Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GYN06-111

A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis

Abstracts/Posters/Presentations:

  • D. Matei, R. Ramasubbaiah, J. Schilder, S. M. Perkins, C. Whalen, T. Breen, C. S. Johnson, M. Callahan, T. Jones, G. Sutton. A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: Hoosier Oncology Group GYN06-111. Accepted to the scientific program in the general poster session at the ASCO Annual Meeting June 4-8, 2010, Chicago, IL. J Clin Oncol 28:15s, 2010 (suppl; abstr 5108)

Manuscripts/Articles:

  • Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial GYN06-111. CANCER, 2008 Aug 15;113(4):723-32. PMID: 18618737
  • R. Ramasubbaiah, S.M. Perkins, J. Schilder, C. Whalen, C.S. Johnson, M. Callahan, T. Jones, G. Sutton, D. Matei. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group: GYN06-111. Gynecologic Oncology (2011). DOI:10.1016/j.ygyno.2011.08.033